EBS   $9.35  2.30% Market Closed After Close 9.31 -0.43%

Emergent BioSolutions Inc
Last Events:

2023-08-09 Signal in EMA20 changed from bearish reversal to bullish reversal. The price is trying to cross up the moving average line If the intersection will be successful, then an upside trend can be formed.

2023-08-06 Trend pattern changed from канал to расширяющаяся формация.

2023-08-06 Signal in Stochastic changed from bullish reversal to bearish recovery. The stochastic indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: main and signal line crossing.

2023-08-06 Signal in RSI changed from bearish to bearish weakening. RSI indicator is in the lower part of the neutral territory and it heading north. These factors indicate that the upside trend is forming Last signal: exit from the overbought zone.

2023-08-04 Signal in RSI changed from bullish to bearish. RSI indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: entrance to the overbought zone.

2023-08-04 Signal in EMA20 changed from bullish reversal to bearish reversal. The price is trying to cross down the moving average line If the intersection will be successful, then a downside trend can be formed.

2023-08-03 Signal in Stochastic changed from bearish weakening to bullish reversal. The stochastic indicator is in the lower part of the neutral territory and left the oversold territory. These factors indicate that perhaps the downside trend is coming to an end price will probably head north Last signal: exit from the oversold zone.

2023-08-03 Signal in RSI changed from bearish weakening to bullish. RSI indicator is in the upper part of the neutral territory and it grows. These factors indicate that positive dynamics persists. Last signal: entrance to the overbought zone.


Current temperature: 2.98
ST: 0, Cor:

50-50 Year Forecast
Low with % probability:
Target: 9.18
High with % probability:
Analyst Recommendations:
Number of estimates 1
Target Price Mean 8.00
Mean unverified/preliminary 8.00 / 8.00
Target Price Low / High 8.00 / 8.00
Median / STD DEV 8.00 / 0.00
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Buy ActivelyBuy ActivelyBuy
rsi ActivelyBuy ActivelyBuy ActivelyBuy
macd None Sell None
stoch Sell None None
ma20 None ActivelyBuy None
ma50 ActivelyBuy None None
ma100 ActivelyBuy ActivelyBuy None
Candlestick PatternOct. 8, 2024 Shooting Star - is a candlestick that has a small body, a long upper shadow and a little or no lower tail. Considered to be a bearish pattern in an uptrend.
ISIN US29089Q1058
ceo Mr. Joseph C. Papa Jr.
Website https://www.emergentbiosolutions.com
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.